-
21.发明授权
公开(公告)号：KR101401468B1
公开(公告)日：2014-05-30
申请号：KR1020120094935
申请日：2012-08-29
Applicant: 전남대학교산학협력단
CPC classification number: C12N9/0071 , C12P17/10 , C12Y114/14001
Abstract: 본 발명은 박테리아 시토크롬 P450을 이용한 아토르바스타틴으로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물에 관한 것으로, 보다 상세하게는 박테리아 시토크롬 P450 BM3(CYP102A1), CYP102A1의 돌연변이체(mutant) 및 CYP102A1의 돌연변이체의 카메라(chimera)를 포함하는 아토르바스타틴으로부터 2-히드록실산물 또는 4-히드록실산물제조용 조성물, 키트 및 이의 생산방법에 관한 것이다.
-
公开(公告)号：KR1020130101493A
公开(公告)日：2013-09-13
申请号：KR1020130102400
申请日：2013-08-28
Applicant: 전남대학교산학협력단
Abstract: PURPOSE: A use of resverastrol derivatives is provided to suppress triggering receptor expressed on myeloid cells-2 (TREM-2) and to regulate the expression of genes related to insulin metabolism and adipocyte differentiation, thereby effectively treating obesity or type 2 diabetes. CONSTITUTION: A method for suppressing TREM-2 in animals exclusive of human comprises the step of administering a composition containing one or more selected among piceatannol, piceid, and pterostilbene as active ingredients to an individual. A method for treating obesity or type 2 diabetes caused by overexpression of TREM-2 gene in animals exclusive of human comprises the step of administering the composition to an individual. A method for increasing the expression of leptin, TNFalpha gene, and adiponectin gene in a TREM-2 transgenic mouse comprises the step of administering the composition to an individual.
Abstract translation: 目的：提供使用白藜芦醇衍生物以抑制在骨髓细胞-2（TREM-2）上表达的触发受体并调节与胰岛素代谢和脂肪细胞分化相关的基因的表达，从而有效治疗肥胖或2型糖尿病。 构成：不包括人类的动物中抑制TREM-2的方法包括向个体施用含有作为活性成分的作为活性成分的作为活性成分的皮质烷醇，皮质和蝶啶中的一种或多种的组合物的步骤。 在不包括人类的动物中，TREM-2基因过表达引起的肥胖症或2型糖尿病的治疗方法包括向个体施用组合物的步骤。 在TREM-2转基因小鼠中增加瘦素，TNFα基因和脂连蛋白基因表达的方法包括向个体施用组合物的步骤。
-
23.发明公开
公开(公告)号：KR1020130055511A
公开(公告)日：2013-05-28
申请号：KR1020120094935
申请日：2012-08-29
Applicant: 전남대학교산학협력단
CPC classification number: C12N9/0071 , C12P17/10 , C12Y114/14001
Abstract: PURPOSE: A composition, a kit, and a method for preparing a 2-hydroxyl product or a 4-hydroxyl product from atorvastatin, are provided to cheaply, efficiently, and selectively produce a large amount of the 2-hydroxyl products or the 4-hydroxyl products, and to develop a novel drug using an atorvastatin metabolite. CONSTITUTION: A composition for preparing a 2-hydroxyl product or a 4-hydroxyl product from atorvastatin contains one or more enzymes selected from the group consisting of wild type CYP102A1, mutant CYP102A1, and a chimera of mutant CYP102A1. A method for preparing the 2-hydroxyl product or the 4-hydroxyl product from atorvastatin comprises a step of reacting the enzymes with atorvastatin. A kit for preparing the 2-hydroxyl product or the 4-hydroxyl product from atorvastatin contains the enzymes and an NADPH-generation system.
Abstract translation: 目的：提供一种组合物，试剂盒和从阿托伐他汀制备2-羟基产物或4-羟基产物的方法，以便廉价，高效地选择性地生产大量的2-羟基产物或4-羟基产物， 羟基产物，并使用阿托伐他汀代谢物开发新药。 构成：用于从阿托伐他汀制备2-羟基产物或4-羟基产物的组合物含有一种或多种选自野生型CYP102A1，突变CYP102A1和突变型CYP102A1嵌合体的酶。 从阿托伐他汀制备2-羟基产物或4-羟基产物的方法包括使酶与阿托伐他汀反应的步骤。 用于制备2-羟基产物或来自阿托伐他汀的4-羟基产物的试剂盒含有酶和NADPH生成系统。
-
24.发明公开박테리아 사이토크롬 피450을 이용한 심바스타틴 또는 로바스타틴의 사람에서의 대사산물의 신규한 생산방법 및 이를 위한 조성물 有权使用细菌细胞色素P450的辛伐他汀或LOVASTATIN的人代谢产物的新方法及其组合物
公开(公告)号：KR1020110020525A
公开(公告)日：2011-03-03
申请号：KR1020090078181
申请日：2009-08-24
Applicant: 전남대학교산학협력단
CPC classification number: C12P17/06 , C12N9/0071 , C12Y114/14001
Abstract: PURPOSE: A method for selective producing human metabolite from simvastatin or lovastatin is provided. CONSTITUTION: A composition for catalysis for producing human metabolite from simvastatin or lovastatin contains wild type CYP102A1 and/or CYP102A1 mutant. The CYP102A1 mutant has 47th amino acid, arginin substituted with leucine; 51th amino acid, tyrosine substituted with phenylalanine; 64th amino acid, glytamic acid substituted with glycine; 74th amino acid, alanine substituted with glycine, 81th amino acid, phenylalanine substituted with isoleucine, 86th amino acid, leucine substituted with isoleucine; 87th amino acid, phenylalanine substituted with valine; 143th amino acid, gluamic acid substituted with glycine; 188th amino acid, leucine substituted with glutamine; and 267th amino acid glutamic acid substituted with valine.
Abstract translation: 目的：提供从辛伐他汀或洛伐他汀选择性生产人类代谢物的方法。 构成：用于从辛伐他汀或洛伐他汀生产人代谢物的催化组合物含有野生型CYP102A1和/或CYP102A1突变体。 CYP102A1突变体具有第47位氨基酸，精氨酸被亮氨酸取代; 第51位氨基酸，被苯丙氨酸取代的酪氨酸; 第64位氨基酸，甘氨酸取代的甘氨酸; 第74位氨基酸，被甘氨酸取代的丙氨酸，第81位氨基酸，被异亮氨酸取代的苯丙氨酸，第86位氨基酸，被异亮氨酸取代的亮氨酸; 第87位氨基酸，用缬氨酸取代的苯丙氨酸; 第143位氨基酸，被甘氨酸取代的谷氨酸; 第188位氨基酸，用谷氨酰胺取代的亮氨酸; 和用缬氨酸取代的第267位氨基酸谷氨酸。
-
25.发明公开대장균에서 발현된 내포체로부터 사람 재조합 Ｂａｘ억제제-1의 리폴딩 및 리포좀으로의 재구성 有权人类重组BAX抑制剂-1在ESCHERICHIA COLI中表达的包含体的脂质体的重构和重构
公开(公告)号：KR1020100090172A
公开(公告)日：2010-08-13
申请号：KR1020090011206
申请日：2009-02-11
Applicant: 전남대학교산학협력단
Abstract: PURPOSE: A method for refolding and recombining recombinant Bas inhibitor-1(BI-1) is provided to use for in vitro functional analysis of BI-1 and to induce Ca^2+ release. CONSTITUTION: A method for producing a liposome containing BI-1 protein comprises: a step of separating an inclusion body containing BI-1 protein; a step of dissolving charotropic agent of first concentration, reductant, and amphoteric surfactant in a first buffer; a step of mixing the first buffer with phospholipid; and a step of exchanging the first buffer to a second buffer. The charotropic agent is urea or guanidiniumchloride.
Abstract translation: 目的：提供重组和重组巴斯抑制剂-1（BI-1）的方法用于BI-1的体外功能分析和诱导Ca 2+释放。 构成：含有BI-1蛋白质的脂质体的制造方法包括：分离含有BI-1蛋白质的包涵体的工序; 将第一浓度，还原剂和两性表面活性剂的二性反应剂溶解在第一缓冲液中的步骤; 将第一缓冲液与磷脂混合的步骤; 以及将第一缓冲器交换到第二缓冲器的步骤。 不合适剂是尿素或氯化胍。
-
Patent Agency Ranking
-
-
28.发明授权
公开(公告)号：KR101538298B1
公开(公告)日：2015-07-29
申请号：KR1020140111204
申请日：2014-08-26
Applicant: 전남대학교산학협력단
IPC: C12N9/02 , C07K14/195 , C12P1/04 , C12Q1/26
Abstract: 본발명은박테리아시토크롬 P450을이용한플루바스타틴으로부터대사산물의신규한생산방법및 이를위한조성물에관한것으로, 보다상세하게는박테리아시토크롬 P450 BM3(CYP102A1), CYP102A1의돌연변이체(mutant) 및 CYP102A1의돌연변이체의카메라(chimera)를포함하는플루바스타틴으로부터 5-히드록실산물및 6-히드록실산물제조용조성물, 키트및 이의생산방법에관한것이다.
-
公开(公告)号：KR1020120112973A
公开(公告)日：2012-10-12
申请号：KR1020110030606
申请日：2011-04-04
Applicant: 전남대학교산학협력단
IPC: A61K31/05 , A61K31/045 , A61K31/09 , A61P3/04
Abstract: PURPOSE: A composition containing TREM-2 inhibitors or resveratol is provided to control the expression of insulin metabolism-related genes and adipocyte differentiation-related genes and to effectively treat obesity or type 2 diabetes. CONSTITUTION: A composition for preventing or treating obesity contains TREM-2(triggering receptor expressed on myeloid cells-2) inhibitors as an active ingredient. The TREM-2 inhibitor is a compound of piceatannol, piceid, or pterostilbene. A composition for preventing or treating obesity or type 2 diabetes contains piceatannol, piceid, or pterostilbene compounds as an active ingredient. The composition for preventing or treating obesity or type 2 diabetes contains a resveratol derivative as an active ingredient.
Abstract translation: 目的：提供含有TREM-2抑制剂或白藜芦醇的组合物，以控制胰岛素代谢相关基因和脂肪细胞分化相关基因的表达，并有效治疗肥胖或2型糖尿病。 构成：用于预防或治疗肥胖症的组合物含有TREM-2（触发骨髓细胞-2表达受体）抑制剂作为活性成分。 TREM-2抑制剂是吡草胺，piceid或p芪烯的化合物。 用于预防或治疗肥胖症或2型糖尿病的组合物含有作为活性成分的皮沙替坦，皮质或p芪烯化合物。 用于预防或治疗肥胖症或2型糖尿病的组合物含有白藜芦醇衍生物作为活性成分。
-
30.发明授权박테리아 사이토크롬 피450을 이용한 심바스타틴 또는 로바스타틴의 사람에서의 대사산물의 신규한 생산방법 및 이를 위한 조성물 有权使用细菌细胞色素P450的辛伐他汀或洛伐他汀人体代谢物的新型制备方法及其组成
公开(公告)号：KR101190881B1
公开(公告)日：2012-10-12
申请号：KR1020090078181
申请日：2009-08-24
Applicant: 전남대학교산학협력단
CPC classification number: C12P17/06 , C12N9/0071 , C12Y114/14001
Abstract: 본 발명은 심바스타틴 또는 로바스타틴의 사람에서의 대사산물을 생산하는 방법에 관한 것이다. 보다 상세하게는, 본 발명은 박테리아 시토크롬 P450 BM3(CYP102A1) 또는 그의 돌연변이체를 이용하여 심바스타틴 또는 로바스타틴으로부터 그의 사람에서의 대사산물을 제조하는 방법 및 이를 위한 조성물 및 키트를 제공한다.
심바스타틴, 로바스타틴, CYP102A1, 돌연변이체
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.024 seconds)
